Dec 21, 2022 · While at UCB, Dr. Jiye Shi, Associate Vice President and Head of Computational Design and Automation Platforms at Eli Lilly and Company, has used machine learning to streamline drug...

May 30, 2023 · XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further...

INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

CAMBRIDGE, Mass., May 30, 2023 /PRNewswire/ -- Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug...

Jan 11, 2023 · Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company.

May 31, 2023 · XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. Innovative techniques used in the TOPAZ trial for Parkinson's disease have ensured that enrolment targets were met, patient participation was boosted, and project costs were reduced.

Aug 16, 2024 · In one deal, Eli Lilly agreed to pay $45 million upfront and up to $1.7 billion in milestones to apply Isomorphic’s technology to discover small-molecule drug candidates for multiple...

May 30, 2023 · Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company.

Aug 20, 2023 · Eli Lilly partnered with XtalPi for up to $250 million to leverage AI and robotics in drug discovery. Lilly’s investment in AI extends beyond drug discovery to include natural language generation, robotic-process automation, and chatbots.

Sep 6, 2024 · Eli Lilly will use Genetic Leap’s RNA-targeted AI platform to develop oligonucleotide drugs for selected targets. The New York biotech said this partnership builds on a successful pilot program with Lilly.